We hypothesized that molecules mimicking the canonical PKC-θ NLS would, in cancer cells, act as specific competitive inhibitors of PKC-θ translocation to the nucleus by preventing access to the importin pathway (Figure 3B). The gene discussed is PRRT2; the disease is cancer.